Beam Therapeutics Presents Preclinical Data Highlighting Utility Of BEAM-302 To Correct An Alpha-1 Antitrypsin Deficiency Disease-Causing Mutation
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in